Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.

doi:10.1016/j.ejca.2024.114158

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.

European journal of cancer (Oxford, England : 1990) - 1 Aug 2024

Kron Anna, Scheffler Matthias, Wiesweg Marcel, Hummel Horst-Dieter, Kulhavy Jonas, Gatteloehner Stefan, Kollmeier Jens, Schubart Christoph, Groß Thorben, Demes Melanie-Christin, Keymel Stefanie, Joosten Maria, Merkelbach-Bruse Sabine, Wölwer Christina Bianca, Tufman Amanda, Kauffmann-Guerrero Diego, Oeser Katharina, Zehaczek Melanie, Jeratsch Ulli, Wolf Juergen

Abstract excerpt

BACKGROUND: This study provides comparative evidence of the selective MET inhibitor capmatinib versus standard of care (SOC) in first-line (1 L) and second-line (2 L) non-small cell lung cancer (NSCLC) patients with METex14 mutations in German routine care. METHODS: SOC data were collected from German routine care via retrospective chart review. Analyses were conducted as naive and propensity score adjusted (PSA)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Carcinoma, Non-Small-Cell Lung

Share to Germany

Share to Imidazoles

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 38941869
DOI: 10.1016/j.ejca.2024.114158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.PMID 38941869Read ↗

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.Semantic proximity Read ↗

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.Semantic proximity Read ↗

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.Semantic proximity Read ↗

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.Semantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.Semantic proximity Read ↗

Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.Semantic proximity Read ↗

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.